Medical Centre Synexus Sofia EOOD
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The site is evaluating innovative treatments for heart failure with preserved or mildly reduced ejection fraction, focusing on reducing systemic inflammation and improving patients’ functional capacity.
- Investigation of anti‑inflammatory agents in heart failure cohorts
- Safety monitoring of emerging cardiovascular drugs
Medical Centre Synexus Sofia EOOD partners with regional cardiology units to bring these studies to the community.
Digestive System Diseases
Research efforts target inflammatory bowel conditions such as moderately to severely active Crohn's disease and ulcerative colitis, aiming to assess long‑term efficacy and safety of novel oral therapies.
- Comparative effectiveness of new biologics versus established treatments
- Evaluation of patient‑reported outcomes in chronic intestinal inflammation
The centre’s gastroenterology team supports these trials to expand therapeutic options for patients.
Immune System Diseases
Studies are centered on chronic urticaria subtypes, including chronic inducible urticaria and chronic spontaneous urticaria, to determine whether new monoclonal antibodies can provide better symptom control.
- Assessment of biosimilar agents for chronic urticaria management
- Exploration of dosing strategies to achieve sustained remission
Medical Centre Synexus Sofia EOOD collaborates with allergy specialists to advance care for these conditions.
Musculoskeletal Diseases
Ongoing investigations address pain relief and bone health, focusing on moderate to severe osteoarthritis of the knee and postmenopausal osteoporosis, with the goal of improving mobility and reducing fracture risk.
- Safety and efficacy of intra‑articular therapies for knee osteoarthritis
- Comparison of biosimilar treatments for bone density enhancement
The orthopedic and endocrinology departments work together to enroll participants locally.
Neoplasms
The centre conducts trials in non‑small cell lung cancer patients who have undergone complete surgical resection, seeking to determine if adjuvant immunotherapy can extend disease‑free survival.
- Evaluation of checkpoint inhibitor combinations after surgery
- Monitoring long‑term outcomes in resected lung cancer cohorts
Medical Centre Synexus Sofia EOOD provides comprehensive oncology support throughout the study period.
Nutritional and Metabolic Diseases
Research includes participants with severe hypertriglyceridemia, aiming to test the impact of novel antisense therapies on lipid levels and cardiovascular risk.
- Analysis of triglyceride reduction efficacy
- Safety profiling of subcutaneous metabolic agents
The metabolic clinic at the centre ensures close monitoring of laboratory parameters.
Respiratory Tract Diseases
Clinical work focuses on adults with moderate-to-severe uncontrolled asthma, evaluating oral compounds that may improve lung function and reduce exacerbations.
- Randomized assessment of new asthma maintenance therapy
- Patient‑centered measurement of symptom control
Medical Centre Synexus Sofia EOOD collaborates with pulmonology experts to recruit and follow participants.
Skin and Connective Tissue Diseases
Trials explore treatments for atopic dermatitis and chronic urticaria, seeking to confirm long‑term safety and effectiveness of emerging biologics.
- Long‑term safety evaluation of skin‑targeted monoclonal antibodies
- Comparative study of biosimilar agents for chronic urticaria
Dermatology specialists at Medical Centre Synexus Sofia EOOD guide patients through the study protocols.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 10 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Novartis Pharma AG1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Centre Synexus Sofia EOOD
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | Boehringer Ingelheim Espana S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG | Phase III | Not Recruiting | Jan 2024 | Jun 2026 |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 2-Amino-9-((2R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl) Tetrahydrofuran-2-Yl)-1,4,5,9-Tetrahydro-6H-Purine-6-Thione | 1 | Unknown | 2023-05-22 | 2023-05-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.